Skip to main content

Table 6 Left ventricular ejection fraction comparison before and after both antibody drug treatments using t-test

From: Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer

Ejection fraction comparison

t-test of paired samples (mean ± SD), %

LVEF1 T versus LVEF2 T

64.69 ± 4.84 versus 60.58 ± 6.58 t = 4.96, df = 25, p < 0.001

LVEF1 TE versus LVEF2 TE

61.75 ± 3.85 versus 59.54 ± 4.12 t = 7.65, df = 23, p < 0.001

LVEF1 T versus LVEF 1 TE

64.69 ± 4.84 versus 61.75 ± 3.85 t = 2.2, df = 23, p = 0.038

LVEF1 T versus LVEF 2 TE

64.69 ± 4.84 versus 59.54 ± 4.12 t = 3.7, df = 23, p = 0.001

LVEF2 T versus LVEF 1 TE

60.58 ± 6.58 versus 61.75 ± 3.85 t = 1.08, df = 23, p = 0.29

LVEF2 T versus LVEF2 TE

60.58 ± 6.58 versus 59.54 ± 4.12 t = 0.36, df = 23, p = 0.716

  1. We used Student’s t-test of paired samples to compare LVEF before and after trastuzumab and trastuzumab emtansine protocols